Eli Lilly And Co (NYSE:LLY) major shareholder Lilly Endowment Inc sold 55,590 shares of Eli Lilly And Co stock in a transaction on Tuesday, September 25th. The stock was sold at an average price of $106.41, for a total transaction of $5,915,331.90. Following the completion of the transaction, the insider now directly owns 119,735,214 shares of the company’s stock, valued at approximately $12,741,024,121.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Lilly Endowment Inc also recently made the following trade(s):

  • On Friday, September 7th, Lilly Endowment Inc sold 180,000 shares of Eli Lilly And Co stock. The stock was sold at an average price of $106.76, for a total transaction of $19,216,800.00.
  • On Thursday, August 30th, Lilly Endowment Inc sold 190,000 shares of Eli Lilly And Co stock. The stock was sold at an average price of $105.42, for a total transaction of $20,029,800.00.
  • On Monday, August 20th, Lilly Endowment Inc sold 195,000 shares of Eli Lilly And Co stock. The stock was sold at an average price of $105.89, for a total transaction of $20,648,550.00.
  • On Wednesday, August 15th, Lilly Endowment Inc sold 151,793 shares of Eli Lilly And Co stock. The stock was sold at an average price of $103.23, for a total transaction of $15,669,591.39.
  • On Friday, August 10th, Lilly Endowment Inc sold 3,587 shares of Eli Lilly And Co stock. The stock was sold at an average price of $103.06, for a total transaction of $369,676.22.
  • On Monday, August 6th, Lilly Endowment Inc sold 195,000 shares of Eli Lilly And Co stock. The stock was sold at an average price of $102.15, for a total transaction of $19,919,250.00.
  • On Thursday, August 2nd, Lilly Endowment Inc sold 190,000 shares of Eli Lilly And Co stock. The stock was sold at an average price of $99.58, for a total transaction of $18,920,200.00.
  • On Tuesday, July 31st, Lilly Endowment Inc sold 205,000 shares of Eli Lilly And Co stock. The stock was sold at an average price of $98.74, for a total transaction of $20,241,700.00.
  • On Tuesday, July 24th, Lilly Endowment Inc sold 185,000 shares of Eli Lilly And Co stock. The stock was sold at an average price of $92.03, for a total transaction of $17,025,550.00.
  • On Thursday, July 5th, Lilly Endowment Inc sold 170,000 shares of Eli Lilly And Co stock. The stock was sold at an average price of $86.62, for a total transaction of $14,725,400.00.

Shares of LLY opened at $106.69 on Friday. Eli Lilly And Co has a 1 year low of $73.69 and a 1 year high of $107.84. The firm has a market cap of $113.52 billion, a PE ratio of 24.93, a PEG ratio of 1.85 and a beta of 0.28. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.40 and a quick ratio of 1.09.

Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings results on Tuesday, July 24th. The company reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.30 by $0.20. Eli Lilly And Co had a negative net margin of 0.60% and a positive return on equity of 39.84%. The company had revenue of $6.36 billion during the quarter, compared to the consensus estimate of $6.05 billion. During the same quarter in the previous year, the company posted $1.11 earnings per share. The company’s revenue for the quarter was up 9.1% compared to the same quarter last year. analysts anticipate that Eli Lilly And Co will post 5.47 earnings per share for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of LLY. Integrated Wealth Concepts LLC bought a new stake in shares of Eli Lilly And Co during the second quarter valued at about $103,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new stake in shares of Eli Lilly And Co during the second quarter valued at about $114,000. Legacy Advisors LLC raised its stake in shares of Eli Lilly And Co by 118.0% during the second quarter. Legacy Advisors LLC now owns 1,354 shares of the company’s stock valued at $116,000 after purchasing an additional 733 shares in the last quarter. Fort L.P. bought a new stake in shares of Eli Lilly And Co during the second quarter valued at about $121,000. Finally, Financial Management Professionals Inc. bought a new stake in shares of Eli Lilly And Co during the second quarter valued at about $128,000. Institutional investors and hedge funds own 76.51% of the company’s stock.

LLY has been the subject of a number of research reports. Morgan Stanley lifted their price objective on shares of Eli Lilly And Co from $93.00 to $102.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 31st. TheStreet downgraded shares of Eli Lilly And Co from a “b” rating to a “c+” rating in a report on Friday, August 24th. Cantor Fitzgerald set a $100.00 price target on shares of Eli Lilly And Co and gave the company a “buy” rating in a report on Tuesday, July 17th. Barclays reissued an “overweight” rating and set a $112.00 price target (up previously from $107.00) on shares of Eli Lilly And Co in a report on Tuesday, September 18th. Finally, SunTrust Banks reissued a “buy” rating and set a $105.00 price target on shares of Eli Lilly And Co in a report on Tuesday, July 31st. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and eleven have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $102.06.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: How to interpret a stock’s beta number

Insider Buying and Selling by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.